(VIANEWS) – The NYSE ended the session with Novo Nordisk A/S (NVO) rising 17.04% to $188.86 on Tuesday while NYSE dropped 0.2% to $16,176.35.
Novo Nordisk A/S’s last close was $161.36, 6.71% under its 52-week high of $172.97.
About Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapy. The company has a collaboration agreement with Gilead Sciences, Inc.; and research collaboration with Novo Nordisk to discover cell-specific carriers of nucleic acid therapeutics. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Earnings Per Share
As for profitability, Novo Nordisk A/S has a trailing twelve months EPS of $4.06.
PE Ratio
Novo Nordisk A/S has a trailing twelve months price to earnings ratio of 46.52. Meaning, the purchaser of the share is investing $46.52 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 83.5%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Novo Nordisk A/S’s stock is considered to be overbought (>=80).
More news about Novo Nordisk A/S (NVO).
